Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
Symbicort in Asthmatic Children - SEEDLING
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 405
- Registration Number
- NCT00651547
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00652002
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00651651
Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 37
- Registration Number
- NCT00643578
- Locations
- 🇺🇸
University of Florida Asthma Research Lab, Gainesville, Florida, United States
A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects
- First Posted Date
- 2008-01-02
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00583947
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
- Conditions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00573222
- Locations
- 🇭🇷
Research Site, Zagreb, Croatia
🇭🇷Croatia, Zadar, Croatia
Change of Inspiratory Peak Flow in COPD
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2007-11-21
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 40
- Registration Number
- NCT00561886
- Locations
- 🇩🇪
Johannes Gutenberg-Univeristy, Mainz, Germany
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 568
- Registration Number
- NCT00557466
- Locations
- 🇬🇧
Novartis Investigator Site, Whitstable, United Kingdom
🇵🇱Novartis Investigator site, Mrozy, Poland
🇩🇪Novartis Investigator Site - 2 sites, Bonn, Germany
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 392
- Registration Number
- NCT00545272
- Locations
- 🇵🇱
Novartis Investigator site, Lubin, Poland
🇩🇪novartis Investigator site, Munchen, Germany
🇷🇺Novartis investigator site, Tomsk, Russian Federation
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)
- Conditions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00443482
- Locations
- 🇩🇪
Novartis Investigative Site, Wiesbaden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.